Immunology Company Kira Biotech launches with A$20M Series A Funding
Related Articles
-
DCR Honours Student has fallen in love with hard work
Kate Chen, promising honours student in the DCR team, wins Concord Hospital Early Career Research Competition. Kate Chen came...
-
Advancing the fight against leukaemia
Featured in ANZAC Institute Discovery, May 2012. Despite substantial advances in treatment options, as many as 60% of patients...
-
New clinical antibody created using the science of gene cloning
Dendritic Cell Research Publish Landmark Paper Dendritic Cell Research (DCR) has a major interest in Dendritic Cell (DC)...
-
John’s Multiple Myeloma Story
Featured in MyeNews, Spring Issue, 2015. John Fullagar gave the consumers perspective at the recent DC Down Under Symposium DC...
-
Anti-cancer vaccine within reach
Featured in Burwood Scene, August 28, 2012. EXCLUSIVE: A 20-strong team of medical researchers led by Professor Derek Hart...
-
An answer to cancer
Featured in Burwood Scene, July 3, 2013. Acute Myeloid Leukaemia is a blood cancer. We know it as bone marrow...
-
ANZAC Research Institute Medical Appeal
Launch Speech by Burwood Scene Editor Belinda Noonan on 29 May 2013. I met Professor Derek Hart at Concord...
-
Global leader predicted for medical research
Featured in Burwood Scene, June 18, 2014. TREASURER Joe Hockey has declared that Australia will become a global leader...
![](mailto:?subject=Immunology Company Kira Biotech launches with A$20M Series A Funding&body=
<img class="aligncenter wp-image-3224 size-medium" src="http://dcresearch.org.au/wp-content/uploads/2019/10/Kira-Biotech-logo-300x150.jpg" alt="" width="300" height="150" /><br />
Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.
The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. <a style="color: #ffcc00;" href="https://kirabiotech.com/wp-content/uploads/2019/10/20191024-Kira-Biotech-Series-A-funding-press-release.pdf">Read More</a>
http://dcresearch.org.au/immunology-company-kira-biotech-launches-with-a20m-series-a-funding/){kind=link}